Cancer Policy FDA releases 10 guiding principles for AI use in drug development January 16, 2026Vol.52 No.02By Sara Willa Ernst
Cancer Policy FDA to increase regulatory flexibility for development of cell and gene therapies January 16, 2026Vol.52 No.02By Jacquelyn Cobb
Drugs & Targets FDA accepts NDA for pimicotinib for treatment of tenosynovial giant cell tumor January 16, 2026Vol.52 No.02
Cancer Policy Merck & Co. drug for treating NSCLC awarded FDA priority voucher January 09, 2026Vol.52 No.1By Claire Marie Porter
Cancer Policy FDA-mandated report finds “insufficient data” to determine safety of PFAS in cosmetics January 09, 2026Vol.52 No.1By Claire Marie Porter
Drugs & Targets FDA grants Enhertu Breakthrough Therapy designation as post-neoadjuvant therapy for HER2+ early breast cancer January 09, 2026Vol.52 No.1
Cancer Policy Angelo de Claro named acting director of FDA Oncology Center of Excellence December 19, 2025Vol.51 No.46By Jacquelyn Cobb
Drugs & Targets FDA grants regular approval to rucaparib for metastatic castration-resistant prostate cancer December 19, 2025Vol.51 No.46
